The IKEA Foundation Commits €10 Million to Provide Emergency Assistance in Türkiye and Northern Syria
The donation will go to Médecins Sans Frontières’ (MSF) emergency fund to provide life saving care where medical needs are the greatest. This will support the delivery of essential aid, including medical assistance, psychological support and healthcare services to those most impacted by the devastating earthquake.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005519/en/
Image credit: Médecins Sans Frontières, Photographer: Omar Haj Kadour (Photo: Business Wire)
The IKEA Foundation is also speaking with other partners who are operating in the region. These partners are coordinating with Turkish authorities to understand further needs and opportunities to provide additional assistance. This includes discussions with Better Shelter, looking at ways to provide modular temporary housing units in Türkiye and Syria.
Per Heggenes, CEO of the IKEA Foundation, said: “We are deeply saddened by the devastation and loss of life in Türkiye and northern Syria following Monday’s earthquakes and especially by the impact on children and their families. Our hearts and thoughts go out to all those who are affected. I call on the world’s governments, businesses, and philanthropies to join us in the relief support for Türkiye and northern Syria.”
The 7.8 magnitude earthquake has so far left at least 7,800 people dead and caused widespread destruction, leaving millions of people wounded and without access to basic healthcare or shelter. Health facilities in the region are facing immense pressure and have limited staff and supplies. Many hospitals are experiencing acute shortages because of high demand to meet the needs of many patients. The situation is particularly acute in northern Syria, where more than 4 million people were already relying on humanitarian assistance.
Stephen Cornish – Director General – Médecins Sans Frontières (MSF) – Operational Center Geneva, said: “We are shocked and saddened by the impact of this disaster. Health facilities are impacted and overwhelmed. Medical personnel in Türkiye and northern Syria are working round the clock to respond to the huge numbers of wounded arriving at facilities. We are deeply thankful to the IKEA Foundation for increasing their donation with an additional €10 million grant to our emergency fund.
About the IKEA Foundation
The IKEA Foundation is a strategic philanthropy that focuses its grant making efforts on tackling the two biggest threats to children’s futures: poverty and climate change. It currently grants more than €200 million per year to help improve family incomes and quality of life while protecting the planet from climate change. Since 2009, the IKEA Foundation has granted more than €1.5 billion to create a better future for children and their families. In 2021 the Foundation decided to make an additional €1 billion available over the next five years to accelerate the reduction of Greenhouse Gas emissions. Learn more at: www.ikeafoundation.org
About Médecins Sans Frontières
Founded in 1971, Médecins Sans Frontières (MSF) is an international, independent medical humanitarian organization, working in more than 70 countries. MSF provides medical assistance to people affected by conflict, epidemics, disasters, or exclusion from healthcare. Learn more at www.msf.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208005519/en/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries1.4.2023 19:18:00 EEST | Press release
REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd. (4755.TW) have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease (aGvHD) in major Asian countries. RGI-2001, with the novel mechanism to improve existing treatments, is a potentially first-in-class small molecule drug candidate targeted for preventing aGvHD, a life-threatening complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). GvHD is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient’s body cells or organs, and leads to skin rash, liver problems, abdominal pain or cramps, diarrhea, and increased risk for infections. Patients undergoing allogeneic HSCT have a high-risk of developing aGVHD associated with significant morb
AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)31.3.2023 19:00:00 EEST | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins. The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States. Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatm
KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”31.3.2023 17:09:00 EEST | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO). This press release features multimedia. View the full release here: https://www.busine
Allianz Appoints Leadership for Allianz Commercial Key Markets31.3.2023 16:11:00 EEST | Press release
As part of the implementation of its ‘Integrated Commercial’ strategy to better serve the full Commercial segment, Allianz Group today announced the leadership for four of its largest Property and Casualty Commercial insurance markets: Australia, France, Germany and the United Kingdom. In each country, the appointed single Commercial lead will represent the integrated Allianz Commercial business and bring to the market Allianz’s full set of solutions for specialty clients, large corporates, and mid-sized companies, simplifying and enhancing the experience of clients and distribution partners. “The appointment of the regional leaders in our core Allianz Commercial markets is an important, concrete step toward realizing our new integrated model, which brings together our Mid Corporate and Large Corporate insurance business for the benefit of our clients and distribution partners,” said Chris Townsend, Member of the Allianz SE Board of Management. Townsend added, “As one face to the marke
Huawei Releases 2022 Annual Report: Steady Operations, Sustainable Survival and Development31.3.2023 12:59:00 EEST | Press release
Huawei released its 2022 Annual Report today. The company reports steady operations throughout 2022, having generated CNY642.3 billion in revenue and CNY35.6 billion in net profits. Huawei continues to strengthen investment in R&D, with an annual expenditure of CNY161.5 billion in 2022, representing 25.1% of the company's annual revenue and bringing its total R&D expenditure over the past 10 years to more than CNY977.3 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005166/en/ (Photo: Huawei) "In 2022, a challenging external environment and non-market factors continued to take a toll on Huawei's operations", said Eric Xu, Huawei's Rotating Chairman, at the company's annual report press conference. "In the midst of this storm, we kept racing ahead, doing everything in our power to maintain business continuity and serve our customers. We also went to great lengths to grow the harvest – generating a steady stream
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom